Renaissance Investment Foundation

Renaissance Investment Foundation is a private investment organization that manages a diverse portfolio in the healthcare and life sciences sectors. The foundation is the primary shareholder of Renaissance Pharma, a clinical-stage biotechnology company dedicated to developing therapies for rare and orphan diseases, particularly in pediatric oncology. Its lead asset, RP-101, is a humanized monoclonal antibody targeting the GD2 antigen, currently in Phase 2 clinical trials for high-risk neuroblastoma. Through its strategic investments, the foundation supports the development of innovative treatments from early-stage research through to clinical validation and commercialization. The organization focuses on addressing significant unmet medical needs in specialized patient populations by providing long-term capital and strategic oversight.